Scientists find a bone-building switch that could fight osteoporosis
Scientists at Leipzig University have identified the GPR133 receptor as a key regulator of bone density. Stimulating this receptor with the substance AP503 has shown promise in increasing bone strength in mice, offering a potential new treatment for osteoporosis.
Why it matters
Osteoporosis affects millions globally, and this discovery could lead to more effective, long-term treatments with fewer side effects than current options.
Osteoporosis, a condition that weakens bones and increases the risk of fractures, affects millions of people and remains a major challenge for doctors seeking safe treatments that can be used over long periods. In Germany alone, about six million people are affected, most of them women.
Because existing therapies can have limitations and side effects, researchers are looking for new biological targets that could lead to more effective ways of preserving or rebuilding bone. Scientists at Leipzig University have now identified one such target in GPR133, a receptor that appears to play an important role in keeping bones strong.
A Little-Known Receptor With a Major Role in Bone Health
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in